Home > Riviste > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Fascicoli precedenti > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2020 June;64(2) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2020 June;64(2):226-30

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi PROMO
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo

 

ORIGINAL ARTICLE   

The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2020 June;64(2):226-30

DOI: 10.23736/S1824-4785.18.03056-X

Copyright © 2018 EDIZIONI MINERVA MEDICA

lingua: Inglese

Predictor of 68Ga PSMA PET/CT positivity in patients with prostate cancer

Cigdem SOYDAL 1 , Yuksel URUN 2, Evren SUER 3, Demet NAK 4, Elgin OZKAN 4, Nuriye O. KUCUK 1

1 Department of Nuclear Medicine, Ankara University Medical Faculty, Ankara, Turkey; 2 Department of Medical Oncology, Ankara University Medical Faculty, Ankara, Turkey; 3 Department of Urology, Ankara University Medical Faculty, Ankara, Turkey; 4 Ankara University Medical Faculty, Ankara, Turkey



BACKGROUND: The aim of this study was to evaluate predictive factors of 68Gallium (68Ga) prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT) positivity.
METHODS: Relationships between serum prostate specific antigen (PSA), lactate dehydrogenase (LDH) and alkaline phosphatase (ALP) levels, Gleason Score (GS) and positivity of 68Ga PSMA PET in patients who underwent 68Ga PSMA PET/CT for restaging for PCa were evaluated retrospectively.
RESULTS: One hundred and four (median age: 67; range: 51-88) patients were included in this study. Of these patients, PSMA PET was positive in 75 (72%) patients. Mean serum PSA levels for PET negative and positive groups were 0.76±1.00 and 180.85±324.93 ng/mL (P<0.001). The sensitivity and specificity of 68Ga PSMA PET/CT for detection of disease recurrence were calculated as 92% and 80%, respectively, for the 1.4 ng/mL PSA cut-off and 92% and 90%, respectively, for the 2 ng/mL PSA cut-off values. The positivity rates for patients with PSA levels <1.4 ng/mL and ≥1.4 ng/mL were 21% and 90%, respectively (P<0.001).
CONCLUSIONS: 68Ga PSMA PET/CT seems to be a highly sensitive in patients with early PSA recurrence. Patients with higher GS and early PSA recurrence could benefit from 68Ga PSMA PET/CT.


KEY WORDS: Neoplasm grading; Positron-emission tomography; Prostatic neoplasms; Prostate-specific antigen

inizio pagina